Avalo Therapeutics (AVTX) Share-based Compensation (2014 - 2026)
Avalo Therapeutics posted quarterly Share-based Compensation of $3.6 million for Q1 2026, up 10.31% year-on-year from $3.2 million in Q1 2025, and down 20.7% on a QoQ basis from $4.5 million in Q4 2025.
Avalo Therapeutics (AVTX) has 13 years of Share-based Compensation data on file, last reported at $3.6 million in Q1 2026.
- For the quarter ending Q1 2026, Share-based Compensation rose 10.31% year-over-year to $3.6 million; the trailing twelve-month figure through Mar 2026 stood at $14.0 million (up 64.87% YoY), and the FY2025 full-year result was $13.6 million, up 132.76% from the prior year.
- Share-based Compensation for Q1 2026 stood at $3.6 million, down from $4.5 million in the prior quarter.
- Across five years, Share-based Compensation topped out at $5.3 million in Q1 2022 and bottomed at $471000.0 in Q2 2024.
- The 5-year median for Share-based Compensation is $953000.0 (2023), against an average of $2.0 million.
- The widest annual swing landed in 2023, when Share-based Compensation plunged 83.9%; it then soared 477.07% in 2025.
- A 5-year view of Share-based Compensation shows it stood at $843000.0 in 2022, then slipped by 7.95% to $776000.0 in 2023, then jumped by 274.23% to $2.9 million in 2024, then soared by 55.23% to $4.5 million in 2025, then dropped by 20.7% to $3.6 million in 2026.
- The last three Share-based Compensation figures came in at $3.6 million (Q1 2026), $4.5 million (Q4 2025), and $3.2 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 892,057.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 305,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 166.40 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 257.40 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 70.15 Mn |
| 10 | Avalo Therapeutics | 317.29 Mn | 317.29 Mn | - | 3.58 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.58 Mn |
| Mar 31, 2026 | 3.58 Mn |
| Dec 31, 2025 | 4.51 Mn |
| Dec 31, 2025 | 4.51 Mn |
| Sep 30, 2025 | 3.15 Mn |
| Sep 30, 2025 | 3.15 Mn |
| Jun 30, 2025 | 2.72 Mn |
| Jun 30, 2025 | 2.72 Mn |
| Mar 31, 2025 | 3.24 Mn |
| Mar 31, 2025 | 3.24 Mn |
| Dec 31, 2024 | 2.90 Mn |
| Dec 31, 2024 | 2.90 Mn |
| Sep 30, 2024 | 1.85 Mn |
| Sep 30, 2024 | 1.85 Mn |
| Jun 30, 2024 | 471,000.00 |
| Jun 30, 2024 | 471,000.00 |
| Mar 31, 2024 | 629,000.00 |
| Mar 31, 2024 | 629,000.00 |
| Dec 31, 2023 | 776,000.00 |
| Dec 31, 2023 | 776,000.00 |
| Sep 30, 2023 | 953,000.00 |
| Sep 30, 2023 | 953,000.00 |
| Jun 30, 2023 | 893,000.00 |
| Jun 30, 2023 | 893,000.00 |
| Mar 31, 2023 | 855,000.00 |
| Mar 31, 2023 | 855,000.00 |
| Dec 31, 2022 | 843,000.00 |
| Dec 31, 2022 | 843,000.00 |
| Sep 30, 2022 | 731,000.00 |
| Sep 30, 2022 | 731,000.00 |
| Jun 30, 2022 | 668,000.00 |
| Jun 30, 2022 | 668,000.00 |
| Mar 31, 2022 | 5.31 Mn |
| Mar 31, 2022 | 5.31 Mn |
| Dec 31, 2021 | 1.89 Mn |
| Dec 31, 2021 | 1.89 Mn |
| Sep 30, 2021 | 1.76 Mn |
| Sep 30, 2021 | 1.76 Mn |
| Jun 30, 2021 | 3.07 Mn |
| Jun 30, 2021 | 3.07 Mn |
| Mar 31, 2021 | 1.45 Mn |
| Mar 31, 2021 | 1.45 Mn |
| Dec 31, 2020 | 1.44 Mn |
| Dec 31, 2020 | 1.44 Mn |
| Sep 30, 2020 | 1.45 Mn |
| Sep 30, 2020 | 1.45 Mn |
| Jun 30, 2020 | 2.79 Mn |
| Jun 30, 2020 | 2.79 Mn |
| Mar 31, 2020 | 1.12 Mn |
| Mar 31, 2020 | 1.12 Mn |
| Dec 31, 2019 | 590,061.00 |
| Dec 31, 2019 | 590,061.00 |
| Sep 30, 2019 | 818,794.00 |
| Sep 30, 2019 | 818,794.00 |
| Jun 30, 2019 | 526,709.00 |
| Jun 30, 2019 | 526,709.00 |
| Mar 31, 2019 | 596,693.00 |
| Mar 31, 2019 | 596,693.00 |
| Dec 31, 2018 | 634,676.00 |
| Dec 31, 2018 | 634,676.00 |
| Sep 30, 2018 | 945,132.00 |
| Sep 30, 2018 | 945,132.00 |
| Jun 30, 2018 | 608,431.00 |
| Jun 30, 2018 | 608,431.00 |
| Mar 31, 2018 | 242,824.00 |
| Mar 31, 2018 | 242,824.00 |
| Dec 31, 2017 | 305,042.00 |
| Dec 31, 2017 | 305,042.00 |
| Sep 30, 2017 | 264,247.00 |
| Sep 30, 2017 | 264,247.00 |
| Jun 30, 2017 | 255,744.00 |
| Jun 30, 2017 | 255,744.00 |
| Mar 31, 2017 | 332,219.00 |
| Mar 31, 2017 | 332,219.00 |
| Dec 31, 2016 | 255,697.00 |
| Dec 31, 2016 | 255,697.00 |
| Sep 30, 2016 | 287,774.00 |
| Sep 30, 2016 | 287,774.00 |
| Jun 30, 2016 | 214,113.00 |
| Jun 30, 2016 | 214,113.00 |
| Mar 31, 2016 | 937,308.00 |
| Mar 31, 2016 | 937,308.00 |
| Dec 31, 2015 | 73,520.00 |
| Dec 31, 2015 | 73,520.00 |
| Sep 30, 2015 | 29,015.00 |
| Sep 30, 2015 | 29,015.00 |
| Jun 30, 2015 | 242,026.00 |
| Jun 30, 2015 | 242,026.00 |
| Mar 31, 2015 | 50,188.00 |
| Mar 31, 2015 | 50,188.00 |
| Dec 31, 2014 | 168,585.00 |
| Dec 31, 2014 | 168,585.00 |